ENDRA Life Sciences (NDRA) Company Report

ENDRA Life Sciences Inc. announced an aggregate of $4.9 million in commitments for a private placement, which is expected to close on or about October 14, 2025.
The offering involves the purchase of 744,340 shares of common stock (or prefunded warrants) and accompanying warrants to purchase up to 1,488,680 shares of common stock, sold at a combined purchase price of $6.57 per unit.
If all warrants are fully exercised for cash, the company could receive total gross proceeds of up to $14.4 million.
The majority of the net proceeds will be used to establish a digital asset treasury (DAT) strategy, managed by Arca Investment Management, LLC, focusing on DeFi sector cryptocurrencies.
The company also intends to appoint Jeff Dorman, Arca's Chief Investment Officer, to its Digital Asset Advisory Board.

Oct 15, 2025, 1:09 PM

ENDRA Life Sciences Announces Private Placement to Fund Digital Asset Treasury Strategy

NDRA

New Projects/Investments

Board Change

ENDRA Life Sciences announced an aggregate of $4.9 million in commitments for a private placement, with potential total gross proceeds of up to $14.4 million if all accompanying warrants are fully exercised for cash.
The majority of the net proceeds will be allocated to establish ENDRA’s digital asset treasury (DAT) operations and accumulate cryptocurrency, managed by Arca Investment Management, LLC, with the balance earmarked for the TAEUS pilot validation imaging study.
The company intends to appoint Jeff Dorman, Arca’s Chief Investment Officer, to its Digital Asset Advisory Board.
The offering includes the purchase of 744,340 shares of common stock (or prefunded warrants) and accompanying warrants to purchase up to 1,488,680 shares of common stock, sold at a combined purchase price of $6.57 per unit.